Why the study?
Opioids remain standard in cardiac surgery, but the beneficial effects of nonnarcotic multimodal analgesia on stress response, recovery, pain, and persistent opioid use are yet to be established.
Do nonopioid analgesics reduce opioid use and improve recovery profiles in patients undergoing cardiac surgery?
Do nonopioid analgesics reduce opioid use and improve recovery profiles in patients undergoing cardiac surgery?
Nonopioid analgesics show promise as opioid-sparing adjuvants in cardiac surgery, but further trials are needed to establish their impact on clinical recovery and persistent opioid use.
Supports multimodal nonopioid regimens for cardiac surgery; extends RCT evidence for opioid-sparing perioperative strategies.
Opioid analgesia is still considered the standard of practice for cardiac surgery. In recent years, combinations of several nonnarcotic analgesics and regional analgesia have shown promise in restricting opioid use during and after cardiac surgery. Ketamine infusion, dexmedetomidine infusion, acetaminophen, ketorolac, and gabapentin are useful adjuvants in cardiac anesthesia practice and have opioid-sparing properties. The beneficial effects of nonnarcotic multimodal analgesia on intraoperative stress response, recovery profile, postoperative pain, and persistent opioid use after cardiac surgery are yet to be established, and further randomized clinical trials are required.
No takes yet. Share an insight, caveat, or question.
Nazarnia et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: